Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 19/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HK1 | P19367 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21032592 | 0.90 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL21032549 | 0.82 | PTGDR2 (0.55) | PTGDR2ALDH1A1HK1SMN1; SMN2HKDC1 | |
| SCHEMBL2670064 | 0.78 | PTGDR2 (0.62) | PTGDR2ALDH1A1HK1SMN1; SMN2HKDC1 | |
| SCHEMBL21031900 | 0.75 | PTGDR2 (0.59) | PTGDR2ALDH1A1HK1SMN1; SMN2HKDC1 | |
| SCHEMBL2670041 | 0.75 | PTGDR2 (0.64) | PTGDR2ALDH1A1HK1SMN1; SMN2HKDC1 | |
| Benzaldehyde SCHEMBL2879447 | 0.74 | PTGDR2 (0.57) | PTGDR2ALDH1A1HK1SMN1; SMN2HKDC1 | |
| SCHEMBL21032892 | 0.73 | ALDH1A1 (0.56) | PTGDR2ALDH1A1HK1SMN1; SMN2HKDC1 | |
| SCHEMBL3187497 | 0.72 | PTGDR2 (0.54) | PTGDR2SMN1; SMN2 | |
| SCHEMBL21031885 | 0.72 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL2670013 | 0.72 | PTGDR2 (0.58) | PTGDR2ALDH1A1HK1SMN1; SMN2HKDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800765-B2 | Indole derivative used as CRTH2 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-10-13 | — | — | US | disclosed |
| US-20190248770-A1 | INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-08-15 | — | — | US | disclosed |
| EP-3489233-A1 | INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248770-A1 | INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | NR3C2, CRHR2, TPH2 | PTGDR2 97/4885ALDH1A1 1366/4885HK1 1806/4885 |
| US-10800765-B2 | Indole derivative used as CRTH2 inhibitor | NR3C2, CRHR2, TPH2 | PTGDR2 97/4885ALDH1A1 1366/4885HK1 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.